Actively Recruiting

Phase 3
Age: 18Years +
All Genders
NCT06743126

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Led by Immatics US, Inc. · Updated on 2026-04-21

360

Participants Needed

59

Research Sites

350 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment with IMA203 administered at the recommended phase 2 dose versus investigator's choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma. For patients interested in additional information on how to participate, please follow this link: https://mytomorrows.com/trials/suprame/en-us/

CONDITIONS

Official Title

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Pathologically confirmed unresectable or metastatic cutaneous melanoma, including acral melanoma
  • Positive for HLA-A*02:01
  • Adequate organ function as defined by the study protocol
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Disease progression on or after at least one PD-1 inhibitor treatment
  • For patients with BRAF mutation, prior treatment with BRAF-directed therapy unless clinically not indicated
  • Life expectancy greater than 6 months
  • Measurable disease per RECIST 1.1 criteria
  • Female patients of childbearing potential must use effective contraception from randomization until 12 months after IMA203 infusion or as per control treatment guidelines
  • Male patients must agree to use effective contraception or abstain during the study and for 6 months after IMA203 infusion or as per control treatment guidelines
  • Recovery to Grade 1 or lower from side effects of prior therapy before randomization
Not Eligible

You will not qualify if you...

  • Primary mucosal or uveal melanoma or melanoma of unknown primary origin
  • History of other malignancies within last 3 years except adequately treated basal or squamous cell carcinoma or carcinoma in situ
  • Serious autoimmune disease unless well controlled without immunosuppressive agents
  • History of specific cardiac conditions as defined by protocol
  • Prior allogenic stem cell or solid organ transplantation
  • Severe or uncontrolled medical conditions that could affect study participation
  • History or current immunodeficiency or treatments compromising immune function
  • Hypersensitivity to cyclophosphamide, fludarabine, IL-2, or rescue medications
  • Positive for HIV or active hepatitis B or C infection
  • Conditions preventing leukapheresis
  • Pregnant or breastfeeding
  • Psychiatric disorders, substance dependence, or neurological impairments interfering with study
  • Recent systemic corticosteroids, surgery, anti-cancer therapies, or investigational drugs before leukapheresis
  • Active or reactivated infections
  • Prior non-myeloablative lymphodepletion within 6 months
  • Prior treatment with IMA203
  • Ascites, pleural or pericardial effusion requiring repeated or continuous drainage
  • Elevated LDH greater than 2.0 times the upper limit of normal
  • Concurrent participation in interfering clinical or device trials
  • Active brain or leptomeningeal metastases
  • Recent investigational therapies, vaccines, corticosteroids, antibiotics, or anti-cancer treatments within specified timeframes
  • Additional criteria as defined by protocol

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 59 locations

1

Mayo Clinic

Phoenix, Arizona, United States, 85054

Actively Recruiting

2

Honor Health Research Institute

Scottsdale, Arizona, United States, 85258

Actively Recruiting

3

City of Hope National Medical Center

Duarte, California, United States, 91010

Actively Recruiting

4

UC San Diego Moores Cancer Center

La Jolla, California, United States, 92093

Actively Recruiting

5

UCLA Hematology/Oncology

Los Angeles, California, United States, 90024

Actively Recruiting

6

UCSF Helen Diller Family Comprehensive Cancer Center

San Francisco, California, United States, 94143

Actively Recruiting

7

Stanford Cancer Center

Stanford, California, United States, 94305

Actively Recruiting

8

University of Colorado, Anschutz Medical Campus

Aurora, Colorado, United States, 80045

Actively Recruiting

9

Yale Cancer Center

New Haven, Connecticut, United States, 06510

Actively Recruiting

10

Mayo Clinic Florida

Jacksonville, Florida, United States, 32224

Active, Not Recruiting

11

University of Miami - Sylvester Comprehensive Cancer Cente

Miami, Florida, United States, 33136

Actively Recruiting

12

Moffitt Cancer Center

Tampa, Florida, United States, 33612

Actively Recruiting

13

University of Chicago Medical Center

Chicago, Illinois, United States, 60637

Actively Recruiting

14

University of MD Greenebaum Comprehensive Cancer Center

Baltimore, Maryland, United States, 21201

Actively Recruiting

15

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114

Actively Recruiting

16

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States, 02215

Actively Recruiting

17

University of Michigan

Ann Arbor, Michigan, United States, 48109

Actively Recruiting

18

Mayo Clinic

Rochester, Minnesota, United States, 55905

Active, Not Recruiting

19

University of Nebraska Medical Center

Omaha, Nebraska, United States, 68198

Actively Recruiting

20

Atlantic Health System/Morristown Medical Center

Morristown, New Jersey, United States, 07960

Actively Recruiting

21

Laura and Isaac Perlmutter Cancer Center at NYU Langone Health

New York, New York, United States, 10016

Actively Recruiting

22

Memorial Sloan Kettering Cancer Center

New York, New York, United States, 10065

Actively Recruiting

23

University of Rochester

Rochester, New York, United States, 14642

Actively Recruiting

24

UNC Hospitals, The University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, United States, 27599

Actively Recruiting

25

Cleveland Clinic, Taussig Cancer Institute

Cleveland, Ohio, United States, 44195

Actively Recruiting

26

Ohio State University

Columbus, Ohio, United States, 43210

Actively Recruiting

27

Providence Cancer Institute Franz Clinic

Portland, Oregon, United States, 97213

Actively Recruiting

28

University of Pennsylvania, Abramson Cancer Center

Philadelphia, Pennsylvania, United States, 19104

Actively Recruiting

29

Thomas Jeffersion University, Sidney Kimmel Cancer Center

Philadelphia, Pennsylvania, United States, 19107

Actively Recruiting

30

Fox Chase Cancer Center

Philadelphia, Pennsylvania, United States, 19111

Actively Recruiting

31

UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania, United States, 15232

Actively Recruiting

32

Avera Cancer Institute

Sioux Falls, South Dakota, United States, 57105

Actively Recruiting

33

SCRI Oncology Partners

Nashville, Tennessee, United States, 37203

Actively Recruiting

34

Baylor University

Dallas, Texas, United States, 75246

Actively Recruiting

35

University of Texas Southwestern Medical Center

Dallas, Texas, United States, 75390

Actively Recruiting

36

The University of Texas MD Anderson Cancer Center

Houston, Texas, United States, 77030

Actively Recruiting

37

Huntsman Cancer Institute, University of Utah

Salt Lake City, Utah, United States, 84112

Actively Recruiting

38

Virginia Commonwealth University

Richmond, Virginia, United States, 23219

Actively Recruiting

39

Fred Hutchinson Cancer Center

Seattle, Washington, United States, 98109

Actively Recruiting

40

BC Cancer - Vancouver

Vancouver, British Columbia, Canada, V5Z 4E6

Active, Not Recruiting

41

University Health Network, Princess Margaret Cancer Centre

Toronto, Ontario, Canada, M5G 2M9

Actively Recruiting

42

Universitatsklinikum Koeln

Cologne, Northrhine-W Estphalia, Germany, 50937

Actively Recruiting

43

Charite Universitaetsmedizin Berlin KöR

Berlin, Germany, 12203

Actively Recruiting

44

Universitaetsklinikum Bonn AöR

Bonn, Germany, 53127

Not Yet Recruiting

45

Technische Universitaet Dresden

Dresden, Germany, 01307

Actively Recruiting

46

Universitaetsklinikum Erlangen AöR

Erlangen, Germany, 91054

Actively Recruiting

47

Universitaetsklinikum Essen AöR

Essen, Germany, 45147

Actively Recruiting

48

Goethe University Frankfurt

Frankfurt am Main, Germany, 60590

Actively Recruiting

49

University Medical Center Hamburg-Eppendorf

Hamburg, Germany, 20246

Actively Recruiting

50

Universitaetsklinikum Heidelberg AöR

Heidelberg, Germany, 69120

Actively Recruiting

51

Universitaet Leipzig

Leipzig, Germany, 04103

Actively Recruiting

52

Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR

Mainz, Germany, 55131

Actively Recruiting

53

Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital

Cambridge, United Kingdom, CB2 0QQ

Not Yet Recruiting

54

Greater Glasgow and Clyde NHS, Beatson West of Scotland Cancer Center

Glasgow, United Kingdom, G12 0YN

Not Yet Recruiting

55

Guy's and St Thomas' NHS Foundation Trust, Guy's Hospital

London, United Kingdom, SE1 9RT

Actively Recruiting

56

The Royal Marsden NHS Foundation Trust

London, United Kingdom, SW3 6JJ

Not Yet Recruiting

57

The Christie NHS Foundation Trust

Manchester, United Kingdom, M20 4GJ

Not Yet Recruiting

58

Oxford University Hospitals NHS Foundation Trust, Churchill Hospital

Oxford, United Kingdom, OX3 7LE

Not Yet Recruiting

59

University of Southampton NHS Foundation Trust, Southampton General Hospital

Southampton, United Kingdom, SO16 6YD

Not Yet Recruiting

Loading map...

Research Team

I

Immatics US, Inc.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma | DecenTrialz